N D Freedman1, T M Curto, C Morishima, L B Seeff, Z D Goodman, E C Wright, R Sinha, J E Everhart. 1. Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA. freedmanne@mail.nih.gov
Abstract
BACKGROUND: Silymarin is the most commonly used herbal product for chronic liver disease; yet, whether silymarin protects against liver disease progression remains unclear. AIM: To assess the effects of silymarin use on subsequent liver disease progression in 1049 patients of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had advanced fibrosis or cirrhosis and had failed prior peginterferon plus ribavirin treatment. METHODS: Patients recorded their use of silymarin at baseline and were followed up for liver disease progression (two point increase in Ishak fibrosis score across baseline, year 1.5, and year 3.5 biopsies) and over 8.65 years for clinical outcomes. RESULTS: At baseline, 34% of patients had used silymarin, half of whom were current users. Use of silymarin was associated (P < 0.05) with male gender; oesophageal varices; higher ALT and albumin; and lower AST/ALT ratio, among other features. Baseline users had less hepatic collagen content on study biopsies and had less histological progression (HR: 0.57, 95% CI: 0.33-1.00; P-trend for longer duration of use=0.026). No effect was seen for clinical outcomes. CONCLUSIONS: Silymarin use among patients with advanced hepatitis C-related liver disease is associated with reduced progression from fibrosis to cirrhosis, but has no impact on clinical outcomes (Clinicaltrials.gov #NCT00006164). Published 2010. This article is a US Government work and is in the public domain in the USA.
BACKGROUND:Silymarin is the most commonly used herbal product for chronic liver disease; yet, whether silymarin protects against liver disease progression remains unclear. AIM: To assess the effects of silymarin use on subsequent liver disease progression in 1049 patients of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had advanced fibrosis or cirrhosis and had failed prior peginterferon plus ribavirin treatment. METHODS:Patients recorded their use of silymarin at baseline and were followed up for liver disease progression (two point increase in Ishak fibrosis score across baseline, year 1.5, and year 3.5 biopsies) and over 8.65 years for clinical outcomes. RESULTS: At baseline, 34% of patients had used silymarin, half of whom were current users. Use of silymarin was associated (P < 0.05) with male gender; oesophageal varices; higher ALT and albumin; and lower AST/ALT ratio, among other features. Baseline users had less hepatic collagen content on study biopsies and had less histological progression (HR: 0.57, 95% CI: 0.33-1.00; P-trend for longer duration of use=0.026). No effect was seen for clinical outcomes. CONCLUSIONS:Silymarin use among patients with advanced hepatitis C-related liver disease is associated with reduced progression from fibrosis to cirrhosis, but has no impact on clinical outcomes (Clinicaltrials.gov #NCT00006164). Published 2010. This article is a US Government work and is in the public domain in the USA.
Authors: Vania Bonifaz; Ying Shan; Richard W Lambrecht; Susan E Donohue; Darcy Moschenross; Herbert L Bonkovsky Journal: Liver Int Date: 2008-08-07 Impact factor: 5.828
Authors: Marc G Ghany; Anna S F Lok; James E Everhart; Gregory T Everson; William M Lee; Teresa M Curto; Elizabeth C Wright; Anne M Stoddard; Richard K Sterling; Adrian M Di Bisceglie; Herbert L Bonkovsky; Chihiro Morishima; Timothy R Morgan; Jules L Dienstag Journal: Gastroenterology Date: 2009-09-18 Impact factor: 22.682
Authors: Chihiro Morishima; Margaret C Shuhart; Chia C Wang; Denise M Paschal; Minjun C Apodaca; Yanze Liu; Derek D Sloan; Tyler N Graf; Nicholas H Oberlies; David Y-W Lee; Keith R Jerome; Stephen J Polyak Journal: Gastroenterology Date: 2009-09-24 Impact factor: 22.682
Authors: Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman Journal: Gastroenterology Date: 2008-09-18 Impact factor: 22.682
Authors: Zachary D Goodman; Anne M Stoddard; Herbert L Bonkovsky; Robert J Fontana; Marc G Ghany; Timothy R Morgan; Elizabeth C Wright; Elizabeth M Brunt; David E Kleiner; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; Jules L Dienstag; Chihiro Morishima Journal: Hepatology Date: 2009-12 Impact factor: 17.425
Authors: Emily J Johnson; Vanessa González-Peréz; Dan-Dan Tian; Yvonne S Lin; Jashvant D Unadkat; Allan E Rettie; Danny D Shen; Jeannine S McCune; Mary F Paine Journal: Drug Metab Dispos Date: 2018-05-07 Impact factor: 3.922
Authors: Sarah J Schrieber; Roy L Hawke; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Catherine M Meyers; Edward Doo; Michael W Fried Journal: Drug Metab Dispos Date: 2011-08-24 Impact factor: 3.922
Authors: Stephen J Polyak; Nicholas H Oberlies; Eve-Isabelle Pécheur; Harel Dahari; Peter Ferenci; Jean-Michel Pawlotsky Journal: Antivir Ther Date: 2012-09-25